Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (USD $)	Total USD ($)	Issuance During Period 1st USD ($)	Issuance During Period 1st Notes Payable USD ($)	Issuance During Period 1st Convertible Notes Payable USD ($)	Issuance During Period 1st Employee Stock Option USD ($)	Issuance During Period 2nd USD ($)	Issuance During Period 2nd Convertible Notes Payable USD ($)	Issuance During Period 2nd Cash USD ($)	Issuance During Period 2nd Private Placement USD ($)	Issuance During Period 3rd USD ($)	Issuance During Period 3rd Private Placement USD ($)	Issuance During Period 4th Notes Payable USD ($)	Issuance During Period 5th Private Placement USD ($)	Issuance During Period 6th Consulting Services USD ($)	Issuance During Period 7th Accrued Liabilities USD ($)	Issuance During Period 8th Private Placement USD ($)	Issuance During Period 9th Private Placement USD ($)	Issuance During Period 10th Private Placement USD ($)	Issuance During Period 11th Private Placement USD ($)	Issuance During Period 12th Cash USD ($)	Issuance During Period 14th USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 1st Private Placement USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock	Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Issuance During Period 3rd USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Period 1 USD ($)	Series C Super Dividend Convertible Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th USD ($)	Series B Preferred Stock USD ($)	Consultant USD ($)	Common Stock USD ($)	Common Stock Issuance During Period 1st	Common Stock Issuance During Period 1st Notes Payable	Common Stock Issuance During Period 1st Employee Stock Option	Common Stock Issuance During Period 2nd USD ($)	Common Stock Issuance During Period 2nd Cash	Common Stock Issuance During Period 3rd USD ($)	Common Stock Issuance During Period 3rd Private Placement USD ($)	Common Stock Issuance During Period 4th Notes Payable	Common Stock Issuance During Period 5th Private Placement	Common Stock Issuance During Period 6th Consulting Services	Common Stock Issuance During Period 7th Accrued Liabilities	Common Stock Issuance During Period 8th Private Placement USD ($)	Common Stock Issuance During Period 9th Private Placement	Common Stock Issuance During Period 10th Private Placement	Common Stock Issuance During Period 11th Private Placement USD ($)	Common Stock Issuance During Period 12th Cash USD ($)	Common Stock Issuance During Period 14th USD ($)	Common Stock Series A 12% Convertible Preferred Stock	Common Stock Series B-1 12% Redeemable Convertible Preferred Stock	Common Stock Series B-2 12% Redeemable Convertible Preferred Stock	Common Stock Series C Super Dividend Convertible Preferred Stock	Common Stock Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th	Common Stock Consultant	Additional Paid-In Capital USD ($)	Additional Paid-In Capital Issuance During Period 1st USD ($)	Additional Paid-In Capital Issuance During Period 1st Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 1st Convertible Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 1st Employee Stock Option USD ($)	Additional Paid-In Capital Issuance During Period 2nd USD ($)	Additional Paid-In Capital Issuance During Period 2nd Convertible Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 2nd Cash USD ($)	Additional Paid-In Capital Issuance During Period 2nd Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 3rd USD ($)	Additional Paid-In Capital Issuance During Period 3rd Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 4th Notes Payable USD ($)	Additional Paid-In Capital Issuance During Period 5th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 6th Consulting Services USD ($)	Additional Paid-In Capital Issuance During Period 7th Accrued Liabilities USD ($)	Additional Paid-In Capital Issuance During Period 8th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 9th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 10th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 11th Private Placement USD ($)	Additional Paid-In Capital Issuance During Period 12th Cash USD ($)	Additional Paid-In Capital Issuance During Period 14th USD ($)	Additional Paid-In Capital Series A 12% Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Additional Paid-In Capital Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series B-2 12% Redeemable Convertible Preferred Stock Issuance During Period 3rd USD ($)	Additional Paid-In Capital Series B-2 12% Redeemable Convertible Preferred Stock Period 1 USD ($)	Additional Paid-In Capital Series C Super Dividend Convertible Preferred Stock USD ($)	Additional Paid-In Capital Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th USD ($)	Additional Paid-In Capital Consultant USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock USD ($)	Series A 12% Convertible Preferred Stock Issuance During Period 1st Private Placement USD ($)	Deficit Accumulated During the Development Stage USD ($)	Deficit Accumulated During the Development Stage Series A 12% Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Deficit Accumulated During the Development Stage Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Deficit Accumulated During the Development Stage Series C Super Dividend Convertible Preferred Stock USD ($)	Deficit Accumulated During the Development Stage Series B Preferred Stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Transaction 01 USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Issuance During Period 2nd USD ($)	Series B-1 12% Redeemable Convertible Preferred Stock Series B Preferred Stock USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 02 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Transaction 03 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Issuance During Period 3rd USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Period 1 USD ($)	Series B-2 12% Redeemable Convertible Preferred Stock Series B Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock USD ($)	Series C Super Dividend Convertible Preferred Stock Issuance During Period 4th USD ($)
Beginning Balance at Jul. 10, 2000
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001 (in shares)																																				114,884
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001	$ 2,221,000																																																											$ 2,221,000
Issuance of shares related to reverse split of common stock																																				3,324
Issuance of restricted common stock																																				454,167
Issuance of restricted common stock																																				1,000																								(1,000)
Issuance of common stock upon exercise of warrants																																				3,419,570
Issuance of common stock upon exercise of warrants	14,307,000																																			3,000																								14,304,000
Issuance of common stock upon exercise of options																																							2,772	398,937
Issuance of common stock upon exercise of options					74,000	362,000																																		1,000																								74,000	361,000
Stock-based compensation expense	11,635,000																																																											11,635,000
Net loss	(71,992,000)																																																																																												(71,992,000)
Issuance of founders shares July 10, 2000 (in shares)																																				2,059,112
Issuance of founders shares July 10, 2000	9,000																																			2,000																								7,000
Convertible preferred stock dividend (in shares)																																																						160,330	298,807	568,721	63,119
Convertible preferred stock dividend																						(47,000)										(33,000)																																																	875,000	1,034,000		2,022,000			224,000							(922,000)	(1,034,000)		(2,022,000)			(257,000)
Beneficial conversion feature	222,000																														1,016,000																													222,000																										1,016,000																								(1,016,000)
Issuance of common stock and beneficial conversion feature related to convertible note in 2001 (in shares)																																				110,054
Issuance of common stock and beneficial conversion feature related to convertible note in 2001	1,036,000																																																											1,036,000
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001 (in shares)																																				203,649
Issuance of common stock in connection with reverse merger of Pro-Pharmaceuticals-NV in 2001	107,000																																																											107,000
Issuance of common stock (in shares)																																						99,705			31,000		537,227	17,647	181,334	2,042	33,618	399,917	219,096	206,019	333,334	1,250,000	2,666,722
Issuance of common stock			1,126,000					602,000			2,861,000	290,000	1,070,000	12,000	302,000	4,410,000	1,319,000	1,898,000	490,000	1,044,000	10,403,000																						1,000					1,000			1,000	1,000	3,000									1,126,000					602,000			2,860,000	290,000	1,070,000	12,000	302,000	4,409,000	1,319,000	1,898,000	489,000	1,043,000	10,400,000
Issuance of Common Stock Warrants				503,000			236,000		261,000	20,000																																																					503,000			236,000		261,000	20,000
Receipt of subscription receivable	150,000																																																											150,000
Reclassification of Warrant Liabilities	3,193,000																																																											3,193,000
Deferred compensation relating to issuance of stock options	455,000																																																											455,000
Stock compensation expense related to fair market revaluation	157,000																																																											157,000
Stock compensation related to the issuance of common shares (in shares)																																				12,515
Stock compensation related to the issuance of common shares	53,000																																																											53,000
Cumulative effect of adoption of new accounting principle	(204,000)																																																											(458,000)																																	254,000
Accretion of redeemable convertible preferred stock																									(1,303,000)			(2,057,000)	(685,000)																																																																			(1,303,000)		(2,057,000)	(685,000)				1,303,000				2,057,000	685,000
Issuance of redeemable convertible preferred stock (in shares)																																																																																												1,742,500												900,000					2,100,000					225
Issuance of redeemable convertible preferred stock																							704,000			1,105,000				2,761,000																																																					1,105,000		2,761,000							704,000												395,000					1,174,000					2,203,000
Stock issued in conversion of convertible securities (in shares)																																					79,367			1,227,972		867,558												30,000				8,334																																	(180,000)																							(5)
Stock issued in conversion of convertible securities		1,745,000				3,948,000				5,330,000																							49,000							1,000		1,000																			1,745,000				3,947,000				5,329,000												72,000							49,000			(72,000)																							(49,000)
Ending Balance at Dec. 31, 2012	1,165,000																																			16,000																								80,535,000																														632,000			(80,018,000)									1,698,000										2,154,000
Ending Balance (in shares) at Dec. 31, 2012																																				16,060,853																																																						1,562,500												900,000										220
Beginning Balance at Dec. 31, 2009
Issuance of common stock (in shares)																											770,000
Ending Balance at Dec. 31, 2010	(1,694,000)																																			11,000																								54,075,000																														644,000			(56,424,000)									1,664,000				2,474,000						2,073,000
Ending Balance (in shares) at Dec. 31, 2010																																				10,651,535																																																						1,592,500												900,000				2,100,000						212
Accretion of beneficial conversion feature for Series B-2	(54,000)																																																																																												(54,000)													54,000
Issuance of restricted common stock																																				20,834
Issuance of common stock upon exercise of warrants																																				1,771,383
Issuance of common stock upon exercise of warrants	7,218,000																																			2,000																								7,216,000
Issuance of common stock upon exercise of options	216,443																																			216,440
Issuance of common stock upon exercise of options	234,000																																																											234,000
Stock-based compensation expense	3,245,000																																																											3,245,000
Net loss	(10,915,000)																																																																																												(10,915,000)
Convertible preferred stock dividend (in shares)																																																						30,321	59,588	139,037	17,066
Convertible preferred stock dividend																						1,000										(33,000)																																																	180,000	378,000		881,000			97,000							(179,000)	(378,000)		(881,000)			(130,000)
Issuance of common stock (in shares)																																																																																																																	13
Issuance of common stock																																																																																																																	130,000
Accretion of redeemable convertible preferred stock																																		(176,000)																																																																			(176,000)				17,000						159,000
Stock issued in conversion of convertible securities (in shares)																																																						5,000			8,334																																		(30,000)																						(5)
Stock issued in conversion of convertible securities																																49,000																																																	12,000						49,000				(12,000)																						(49,000)
Ending Balance at Dec. 31, 2011	(2,125,000)																																			13,000																								66,367,000																														632,000			(69,137,000)									1,681,000				2,687,000						2,154,000
Ending Balance (in shares) at Dec. 31, 2011																																				12,919,538																																																						1,562,500												900,000				2,100,000						220
Accretion of beneficial conversion feature for Series B-2	(56,000)																																																																																												(56,000)													56,000
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001 (in shares)																																				2,666,722
Issuance of common stock and warrants, net of issuance costs of $1,597,000 in 2012 and $17,000 in 2001	10,403,000																																			3,000																								10,400,000
Issuance of shares related to reverse split of common stock																																				3,324
Issuance of common stock upon exercise of warrants																																				12,177
Issuance of common stock upon exercise of options	51,830																																			51,830
Stock-based compensation expense	2,766,000																																																											2,766,000
Net loss	(9,675,000)																																																																																												(9,675,000)
Convertible preferred stock dividend (in shares)																																																						31,250	95,584	223,027	46,053
Convertible preferred stock dividend																																(123,000)																																																	103,000	224,000		522,000			127,000							(103,000)	(224,000)		(522,000)			(127,000)
Issuance of common stock (in shares)																																																											11,348
Issuance of common stock	68,800,000																																		26,000																																																						26,000
Accretion of redeemable convertible preferred stock																																		(174,000)																																																																			(174,000)				17,000						157,000
Ending Balance at Dec. 31, 2012	$ 1,165,000																																			$ 16,000																								$ 80,535,000																														$ 632,000			$ (80,018,000)									$ 1,698,000				$ 2,900,000						$ 2,154,000
Ending Balance (in shares) at Dec. 31, 2012																																				16,060,853																																																						1,562,500												900,000				2,100,000						220